Fresenius Kabi Oncology

Of the total borrowings during the month, USD 1.02 billion were raised through automatic route while USD 330 million came via approval route.

AstraZeneca delisting: Time for Sebi to amend guidelines?

AstraZeneca Pharma today said that its board would be meeting on Wednesday to consider a proposal to delist the company.

Fresenius Kabi standalone Dec '13 sales at Rs 84.66 crore

Fresenius Kabi Oncology has reported a standalone sales turnover of Rs 84.66 crore and a net loss of Rs 63.63 crore for the quarter ended Dec '13

Stocks in news: Sterling Holidays, Power Grid, Tata Chem

Tech Mahindra | Jubilant Foodworks | Prestige Estates | Wheels India | Tata Chemicals | Future Lifestyle | P&G | Divis Labs | JP Power | JP Infra | Power Grid Corporation | Engineers India | Thomas Cook | Sterling Holidays | NCC and Novartis India are stocks, which are in the news today.

Fresenius Kabi standalone Sep '13 sales at Rs 96.15 crore

Fresenius Kabi Oncology has reported a standalone sales turnover of Rs 96.15 crore and a net loss of Rs 44.79 crore for the quarter ended Sep '13

Fresenius Kabi gets 2 months extension for delisting offer

Earlier this month the company had said that Securities and Exchange Board of India (SEBI) had advised it to approach Securities Appellate Tribunal (SAT) for seeking any relief, including extension of time.

Fresenius Kabi up as SAT sets aside SEBI's delisting order

SAT says that the company is not need to comply with SEBI's conditions. Fresenius kabi had moved to SAT against SEBI's conditional nod for delisting.

Fresenius Kabi Oncology surges 12% on FDI approval

Parent company Fresenius Kabi (Singapore) Private Limited holds 81 percent stake in the company as of June 2013. The Royal Bank of Scotland Asia Merchant Bank (Singapore), Macquarie Bank, Morgan Stanley Asia (Singapore) PTE and Nomura Singapore have 6.85 percent stake.

Fresenius Kabi standalone Jun '13 sales at Rs 126.87 crore

Fresenius Kabi Oncology has reported a sales standalone turnover of Rs 126.87 crore and a net profit of Rs 4.80 crore for the quarter ended Jun '13

Fresenius Kabi hits 52-week high on FIPB nod, gains 9%

The Foreign Investment Promotion Board (FIPB) on Monday cleared six proposals envisaging investments of Rs 855 crore in the pharmaceutical sector, including Fresenius Kabi.

Buy Fresenius Kabi, Tech Mahindra; sell Titan Ind: Agarwal

According to Abhishek Agarwal of Fortune Interfinance, one may buy Fresenius Kabi Oncology with a target price of Rs 155 and a stop loss of Rs 140 and sell IDFC.

USFDA issues warning letter to Fresenius Kabi Oncology

The US Food and Drug Administration (USFDA) has issued a warning letter to Fresenius Kabi Oncology for violation of manufacturing norms at its Kalyani facility in West Bengal.

Go long on Fresenius Kabi, M&M Financial, Biocon: Diwan

According to Prakash Diwan of Altamount Capital Management, one may go long on Fresenius Kabi Oncology and advises to go long on Mahindra & Mahindra Financial Services with a target price of Rs 267 and a stop loss at Rs 250.

Buy Fresenius Kabi Oncology, target of Rs 140: SP Tulsian

According to SP Tulsian of sptulsian.com, one can enter Fresenius Kabi Oncology at current price with a near term target of Rs 140.

Fresenius Kabi Oncology up 20% on SEBI's nod for delisting

Allowing Fresenius Kabi Oncology to initiate the delisting process, Sebi however, said that the company would have to take into account its pre-OFS (Offer for Sale) promoter holding of October 2012 to determine the minimum number of shares to be acquired for the delisting.

Sebi allows Fresenius Kabi Oncology to delist shares

Capital market regulator Sebi on Monday allowed Fresenius Kabi Oncology to delist its shares from the Indian stock market and asked the healthcare firm to complete the delisting process within three months -- bringing to an end a long-standing dispute.

USFDA issues warning letter to Fresenius Kabi

Fresenius Kabi Oncology in Friday said it has received a warning letter from the US health regulator asking for more information and implementation of additional corrective and preventive measures regarding GMP non- conformities.

Fresenius Kabi soars 5% on delisting buzz

Fresenius Kabi Oncology gained as much as 20 percent intraday on Wednesday after the company said parent company was looking for voluntary delisting of Indian arm. But the stock came off day's high on profit booking.

Buy Godrej Ind, Raymond, Fresenius Kabi: Merani

In CNBC-TV18's popular show Bull's Eye, Nooresh Merani, AMSEC Research shares trading strategy of the day.

Fresenius Kabi standalone Dec '12 sales at Rs 205.04 crore

Fresenius Kabi Oncology has reported a sales standalone turnover of Rs 205.04 crore and a net profit of Rs 48.36 crore for the quarter ended Dec '12

Action-packed weeks ahead for MNC stock: Analysts

Shares of multi-national companies (MNCs) will be in focus in the next few weeks as many of them will be required to either reduce promoter shareholding to a regulatory cap of 75 per cent or get delisted.

Fresenius Kabi Sep '12 sales at Rs 164.53 crore

Fresenius Kabi Oncology has reported a sales turnover of Rs 164.53 crore and a net profit of Rs 26.95 crore for the quarter ended Sep '12

Fresenius Kabi Jun '12 sales at Rs 133.49 crore

Fresenius Kabi Oncology has reported a sales turnover of Rs 133.49 crore and a net profit of Rs 13.04 crore for the quarter ended Jun '12

Pharma sector outperforms in Q4FY12: UR Associates

UR Associates has come out with its report on pharma sector. The results season has finally come to an end and expectedly pharma sector has outperformed many other sectors.

Fresenius Kabi Mar '12 sales at Rs 121.79 crore

Fresenius Kabi Oncology has reported a sales turnover of Rs 121.79 crore and a net profit of Rs 4.88 crore for the quarter ended Mar '12